CClinicalTrials.gg
TerminatedNCT04405024HOSPI-VHCUpdated Sep 15, 2026

Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients

An interventional study of Hepatitis C testing in Hepatitis C, sponsored by Centre Hospitalier Intercommunal Creteil. Terminated at 4 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Centre Hospitalier Intercommunal Creteil · Not applicable, Interventional, and Diagnostic

Why this study was terminated
The study was prematurely terminated due to major recruitment difficulties. Indeed, only one site was opened and participated in the study, with inclusions carried out in 2020.
Phase
Not applicable
Study type
Interventional
Enrollment
117
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The Ministry of Health has set the target of eradicating hepatitis C (HCV) in France by 2025.

The goal is to validate the feasibility and value of conducting routine HCV screening in hospitalized patients.

Read the detailed description

The number of undetected HCV-infected persons has been extrapolated to 75,000 according to the results of a 2014 study. Screening efforts have been set up in groups of people said to be at high viral risk: drug users, prisoners, precarious persons or migrants from highly endemic countries. Nevertheless, the concept of universal screening has not yet been adopted by the guardians and the Ministry.

It is in this context that "hepatitis free hospital" projects have been carried out in several French cities such as Nice, Nancy and Marseille.

The aim of the HOSPI-VHC study is to evaluate the feasibility and efficiency of systematic HCV screening in all medical and surgical departments of 4 National Association of Hepato-Gastroenterologists of General Hospitals (ANGH) hospitals. This pilot project is part of a public health screening program. It will evaluate the interest and usefulness of implementing universal screening in hospitalized patients without taking into account the existence of viral risk factors. This study will also make it possible to evaluate the implementation of a dedicated care pathway: number of patients screened, number of patients referred for consultation and number of patients accepting the consultation.

02

Conditions studied

  • Hepatitis C

Browse trials for

03

In context

Hepatitis C

2,321 studies on the registry are indexed under Hepatitis C; 102 are open to participants now.

This study's enrollment of 117 is above the median of 79 across 1,633 interventional studies indexed under Hepatitis C.

Browse Hepatitis C studies →

Lead sponsor

Centre Hospitalier Intercommunal Creteil is the lead sponsor of 131 studies on the registry; 36 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Patient over 18 years of age
  • Hospitalized during the study period
  • Non-opposition for participation in the Protocol

Exclusion criteria

Exclusion Criteria:

  • Patients under 18 years of age
  • Outpatient, long-stay, maternity and intensive care inpatients
  • Patients refusing blood collection
  • Patient may not understand the information sheet
  • Patient under guardianship
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
117 participants (actual)

Study arms

  • Other
    Hepatitis C testing

    If the patient is included in the study, HCV serology (2 x 5 ml tubes) will be taken at the time of admission as part of the routine entry assessment. These two tubes will be used for HCV screening. The patient is informed of the HCV serology result during hospitalization by an investigator.

    Diagnostic Test: Hepatitis C testing

Interventions

  • Diagnostic testHepatitis C testing

    Hepatitis C Screening

06

What researchers measure

Primary outcomes

  1. potential patient versus

    Number of HCV serologies collected compared to the number of patients meeting the inclusion criteria during the study period.

    Time frame: 7 days

Secondary outcomes

  1. HCV positive

    Percentage positive for HCV

    Time frame: 7 days

  2. Follow-up

    Percentage of patients referred for consultation if HCV positive

    Time frame: 2 months

  3. Polymerase chain reaction (PCR)

    Percentage of HCV PCR positive patients

    Time frame: 7 days

  4. Viral risk factor

    Percentage of patients with a viral risk factor

    Time frame: 7 days

  5. hepatic fibrosis

    Percentage of patients with hepatic fibrosis

    Time frame: 7 days

  6. treatment initiation

    Percentage of patients benefiting from treatment initiation

    Time frame: 2 months

07

Study locations

4 sites
  • CHI Créteil
    Créteil, 94000, France
  • Grand Hôpital de l'Est Francilien - Site de Marne-la-Vallée
    Jossigny, France
  • CH Meaux
    Meaux, France
  • CHIV
    Villeneuve-Saint-Georges, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04405024
Lead sponsor
Centre Hospitalier Intercommunal Creteil
Collaborators
Association Nationale des Hépato-Gastroentérologues des Hôpitaux Généraux
Responsible party
Sponsor
First posted
May 28, 2020
Start date
Sep 21, 2020
Primary completion
Sep 29, 2020
Completion
Sep 29, 2020
Last update
Sep 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion